Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Danaher

Danaher Earnings Preview: What to Expect

Healthcare giant Danaher is set to unveil its fourth-quarter earnings later this month and analysts expect a modest single-digit growth in earnings.

Barchart

How Is Danaher’s Stock Performance Compared to Medical Devices Stocks

Danaher has underperformed the Medical Devices industry, though Wall Street analysts remain strongly optimistic about its future prospects.

Barchart

What Are Wall Street Analysts' Target Price for Danaher Stock?

Although Danaher has underperformed relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What You Need to Know Ahead of Danaher's Earnings Release

With Danaher gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings decline.

Barchart

Danaher Stock: Is DHR Underperforming the Healthcare Sector?

Danaher recently underperformed the healthcare sector, but Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

Danaher Stock: Is Wall Street Bullish or Bearish?

Danaher has lagged behind the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Barchart

Stocks Finish Higher as Q1 Earnings Impress

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +1.20%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.51%. US stock indexes closed moderately higher on Tuesday, with the Dow Jones Industrials climbing...

Barchart

Read news from The Economist, FT, and more,
with one subscription

Veralto: The Unassuming ESG Powerhouse That Will Likely Double

In the specialized field of spinoff companies, Veralto emerges as a prime investment opportunity, stemming from its recent spinoff from Danaher Corporation.

Barchart

Danaher (DHR) vs. Stryker (SYK) - Analyzing Anticipated Q4 Earnings

With rapidly increasing healthcare demands, numerous technological breakthroughs, and advanced research and development, the medical industry is well-poised for remarkable growth and profitability. As medical companies Danaher (DHR) and Stryker (SYK) gear to report their fourth-quarter earnings tomorrow, let’s determine if these stocks are ideal buys ahead of earnings….

StockNews.com

Danaher Corp Has Unusual Stock Options Activity - Highlighting Value in DHR Stock

Danaher Corp, the biotech/life sciences products firm, has had unusual call options activity today. It highlights the value of shorting out-of-the-money "covered calls" in DHR stock as an income play.

Barchart

Private equity's hiring spree is upending the Fortune 500 C-suite

PE firms need CEOs to run their fast-growing portfolio companies and are draining succession talent from public companies.

Fortune

Staffordshire-based Instem bought by private equity group for £203m

Instem is second UK life sciences company this week to be snapped up by a foreign buyer

The Guardian - UK

Stocks Close Slightly Higher Despite Bank Stock Weakness and Hawkish Fed Comments

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.09%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.03%. The S&P 500 and Nasdaq 100 indexes Tuesday settled...

Barchart

2 Stocks to Buy Now at Knocked-Down Prices

With steady growth in employment during November, slower but surer interest rate hikes by the Fed to fight inflation threaten to keep markets subdued and the economy sluggish next year. Therefore, it could be wise to load up on shares of businesses with robust demand and a stable growth trajectory,…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022

Upgrades

Benzinga

Check Out What Whales Are Doing With DHR

Someone with a lot of money to spend has taken a bullish stance on Danaher (NYSE:DHR). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Danaher Whale Trades For October 04

A whale with a lot of money to spend has taken a noticeably bearish stance on Danaher. Looking at options history for Danaher (NYSE:DHR) we detected 10 strange trades.

Benzinga

This Is What Whales Are Betting On Danaher

A whale with a lot of money to spend has taken a noticeably bearish stance on Danaher. Looking at options history for Danaher (NYSE:DHR) we detected 10 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

How Is The Market Feeling About Danaher?

Danaher's (NYSE:DHR) short percent of float has fallen 7.35% since its last report. The company recently reported that it has 3.99 million shares sold short, which is 0.63% of all regular shares that are available for trading.

Benzinga

Here's How Much $100 Invested In Danaher 20 Years Ago Would Be Worth Today

Danaher (NYSE:DHR) has outperformed the market over the past 20 years by 7.67% on an annualized basis producing an average annual return of 14.78%. Currently, Danaher has a market capitalization of $186.88 billion.

Daily Mirror

'Skin and bones' dog unrecognisable after being rescued by RSPCA

Lurcher Emily weighed just 10.8kg when she was taken into the RSPCA's Danaher Animal Home's care - but thankfully she was quickly snapped up by a lovely new family

Benzinga

$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

Danaher (NYSE:DHR) has outperformed the market over the past 10 years by 9.25% on an annualized basis producing an average annual return of 20.62%. Currently, Danaher has a market capitalization of $184.66 billion.

Benzinga

Danaher's Defensive Portfolio Is Ideal Amid Macro Fears: RBC Analyst

Danaher Corporation’s (NYSE: DHR) portfolio, with 75% recurring revenues and more than a 90% mix in life sciences and diagnostics, appears “incrementally more attractive” amid the currently harsh macro environment, according to RBC Capital Markets.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

Upgrades

Benzinga

Peering Into Danaher's Recent Short Interest

Danaher's (NYSE:DHR) short percent of float has fallen 5.0% since its last report. The company recently reported that it has 4.92 million shares sold short, which is 0.76% of all regular shares that are available for trading.

1 2 3

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.